A group of scientists have claimed to have created functional liver cells from human embryonic and genetic engineered stem cells.
Human liver cells, called hepatocytes, are in short supply as they can only be isolated from donated organs.
Scientists from the Hebrew University of Jerusalem reported that they have produced large amounts of functional liver cells, and Prof. Yaakov Nahmias, study's senior author, added that this was quite a revolution for pharmaceutical drug discovery.
The pharmaceutical companies spend USD 1 billion each year on liver cells alone, and producing an unlimited supply of functional liver cells from human pluripotent stem cells can change that he added.
Nahmias's team further discovered that the bacteria populating the infant gut moments after birth produced vitamin K2 and bile acids that activated the fetal liver's dormant drug metabolism program.
It demonstrated that liver cells are produced from either embryonic stem cells or genetically engineered skin cells and could detect the toxic effect of over a dozen drugs with greater than 97 percent accuracy.
The study is published in the journal Hepatology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
